ALAN SNYDER

Managing Partner - Shinnecock Partners

Art Lending

Alan is the Founder and Managing Partner of Shinnecock Partners. Alan was the Founder, CEO, President, and Chairman of the Board of Answer Financial Inc and Insurance Answer Center, CEO of Aurora National LIfe Assurance, President/COO of First Executive Corporation and Executive Vice President and member of the Board of Directors at Dean Witter Financial Services Group (predecessor to Morgan Stanley) where he formulated the launch of the Discover Card as a member of a three-person team. He is also the former Chairman, President and Board Member of the Western Los Angeles Boy Scout Council. Alan is a graduate of Georgetown University and Harvard Business School, where he was a Baker Scholar.

LARRY POWELL

Founder - LP Institutional

Larry Powell is the former Deputy CIO of the Utah Retirement Fund, where he comanaged a $25B US Public Pension Plan. Mr. Powell joined URS in 2008 and he was ultimately responsible for the oversight and management of the investment team, analyzing deals and investing in all global public and private market asset classes. He worked with the URS investment team in all aspects of the investment management process, including manager sourcing, due diligence, buy/sell decisions, fee and term negotiations as well as the tactical and strategic investing of the URS portfolio.

Mr. Powell is currently President of LP Institutional, a consulting firm advising institutional investors and asset managers on issues such as allocation of capital, investment opportunities, best practices and governance.

Prior to joining URS, Mr. Powell served initially as PM Alternative Assets, investing across asset classes private and public, before being promoted to Managing Director of External Public Markets at the Teacher Retirement System of Texas, where he oversaw nearly 40% of the $115B in plan assets. In this role, he created and obtained approval for an external manager initiative based on an Optimal Endowment Portfolio, transitioning the plan from 10% to 80% externally managed. Mr. Powell managed a team of ten professionals who collectively oversaw TRS’ global investments in external managers within equities, fixed income and hedge funds.

ALEC ANDRONIKOV

General Partner - NDCapital

Private Equity

As a seasoned investor and operator, Alec spent 15+ years backing, scaling and driving highly-favorable exit outcomes for rockstar teams and products that realize the future of innovative yet scalable mobile-first technologies. These included MoVoxx – industry-first SMS ad platform (acquired by MOTR for $100mm); inFreeDA – free 411 voice targeting platform (acquired by AT&T); AdCel – mobile mediation platform (acquired by Engage:BDR).

Alec’s investment activity includes raising/founding advantEdge, India-focused early stage venture cross-border fund (top 2% of global venture fund performance 2015-2017); limited partner at Eniac Ventures, the first mobile-focused early stage fund; EIR at Capital Factory in Austin.

Alec started his investment career in corporate finance at JPMorgan’s media and telecommunications leveraged finance group in New York.

Alec graduated with a double Honors degree in Economics and Business Administration at the Haas School of Business from the University of California, Berkeley. He is a regular speaker at conferences such as SXSW, TechCrunch, CES, Digital Hollywood, iMedia, and Advertising Week. In his spare time, Alec enjoys international travel, cross country biking and wine tasting – though not always in the same order.

DR JASON KRALIC

Director of Business Development

Bioscience Pharma Partners<

Jason Kralic, Ph.D. is Director of Business Development for Bioscience Pharma Partners. He brings broad experience in technology innovation, R&D, licensing and company creation. Jason was formerly Global Head of Neurosciences Business Development at GlaxoSmithKline during which he led the divestment of GSK’s Ph3- ready Alzheimer’s disease program, Intepirdine, to Axovant resulting in a $360M IPO (largest of 2016) and helped launch several start-up companies, including Convergence Pharmaceuticals (received $200M upfront from Biogen for license to neuropathic pain programs), PainQx (raised $5M in non-dilutive and equity funding for pain diagnostics platform) and Care Directions (>$300,000 funding for healthcare IT solution for post-stroke management). He also served at AVP Technology Innovation at Wake Forest Baptist Medical Center, as VP Business Development at Opexa Therapeutics and co-founded Tellus Therapeutics focused on the development of treatments for neonatal brain injury. He serves on the scientific advisory board for the Alzheimer’s disease company, T3D Therapeutics. Jason holds a Ph.D. in pharmacology, with a focus on neuropharmacology, from the University of North Carolina at Chapel Hill and completed post-doctoral training at the University of Zurich.